Acambis plc, of Cambridge, England, appointed Gordon Cameron president and Geoffrey Porges and Michael Lytton as nonexecutive directors of its board.
Achillion Pharmaceuticals Inc., of New Haven, Conn., added Mingjun Huang as director of molecular virology, Doug Buechter as director of molecular biology and biochemistry and Erin Duffy as associate director of computational chemistry and informatics.
Antigenics Inc., of New York, elected Sanford Litvack to its board.
Austrian Nordic Biotherapeutics AG, of Vienna, Austria, added Thomas Fischer as chief financial officer.
BioStratum Inc., of Research Triangle Park, N.C., appointed Gary Gordon vice president of business development.
Deltagen Inc., of Menlo Park, Calif., appointed William Scott to its board and Erick Zimmer director of commercial development.
Dyax Corp., of Cambridge, Mass., promoted Scott Chappel to executive vice president of research and development, and added Jessica Wolfe as director of investor relations and Elaine Rosenberg Crowley as senior vice president of human resources.
DynaGen Inc., of Needham, Mass., named Jay Wadekar president and chief operating officer.
Epicyte Pharmaceutical Inc., of San Diego, added Vincent Gotz as vice president of business development.
GPC Biotech AG, of Martinsried, Germany, appointed Benno Rattel senior director of drug development. Jerome Birnbaum, Stephen Carter and Prasad Sunkara will serve as consultants on its preclinical and clinical development advisory panel.
Immunex Corp., of Seattle, elected Robert Herbold to its board.
Inspire Pharmaceuticals Inc., of Durham, N.C., added Mary Bennett as vice president, operations and communications and Mark Montgomery as senior director, intellectual property/legal.
Lexicon Genetics Inc., of The Woodlands, Texas, elected Robert Lefkowitz to its board.
Mary Woodard Lasker Charitable Trust, of New York, named Samuel Silverstein president of Funding First, its medical and health research policy program.
MdBio Inc., of Frederick, Md., added Wayne Hockmeyer, Nancy Spangler and Robert Eaton to its board. Rachel King is now the chair.
Panacea Pharmaceuticals Inc., of Rockville, Md., appointed Michael Rosen operations and technical director for its diagnostic division.
Protogene Laboratories Inc., of Menlo Park, Calif., appointed David Kern director, program management.
SYN X Pharma Inc., of Toronto, added Aaron Davidson as vice president, business development.
Targeted Genetics Corp., of Seattle, formed the board of directors for CellExSys Inc., its majority-owned subsidiary. The initial members are Edward Lanphier, Thomas Wiggans, David Schubert and H. Stewart Parker. Parker, CEO of Targeted Genetics, will serve as chairman.
V.I. Technologies Inc., of Watertown, Mass., appointed Joseph Limber to its board. Limber is president and CEO of Aclara BioSciences Inc., of Mountain View, Calif.